Morphotek Inc. (A subsidiary of Eisai), Email Format
Biotechnology ResearchPennsylvania, United States51-200 Employees
Morphotek Inc., a subsidiary of Eisai, operates in the biotechnology research sector and develops monoclonal antibody–based products to treat cancer, inflammation, and infectious diseases. Founded in 2000 and based in Exton, Pennsylvania, the company pursues discovery and development of antibody therapies using its proprietary technologies. This activity places Morphotek within the life sciences field as a contributor to biologic therapies derived from antibodies. It collaborates with academic institutions and industry partners and pursues licensing arrangements to advance its antibody programs to broader markets. In 2017, Morphotek and The Rockefeller University entered into a Sponsored Research Agreement to explore how the CA125 tumor shed antigen may suppress immune-based therapies.